Drs. Christian Griñán-Ferré, Ariadna Boloix, & Aina Bellver
Flavii Therapeutics is a new spin-off created by researchers from the Institute of Neurosciences of the University of Barcelona (UBneuro) and the Faculty of Pharmacy and Food Sciences. The company is co-founded by Dr. Christian Griñán-Ferré, researcher at UBneuro and professor at the Department of Pharmacology, Toxicology and Therapeutic Chemistry, together with Dr. Aina Bellver and Dr. Ariadna Boloix.
Flavii Therapeutics focuses on the development of epigenetic-based drugs to prevent and treat Alzheimer’s disease and other neurodegenerative disorders. Its approach targets the molecular mechanisms that regulate gene expression (specifically, epigenetic changes associated with aging and environmental factors) which play a critical role in the progression of these diseases.
The project originates from ongoing research led by Dr. Griñán-Ferré’s group at the Institute of Neurosciences, where the team has designed a new class of G9a methyltransferase inhibitors. These compounds show high potency and selectivity, are able to cross the blood–brain barrier, and have demonstrated significant improvements in Alzheimer’s disease biomarkers in preclinical models. This innovative pharmacological strategy represents a shift in paradigm from conventional Alzheimer’s treatments, which have traditionally focused on reducing beta-amyloid or Tau protein accumulation. Instead, Flavii Therapeutics acts on early epigenetic mechanisms that underlie neurodegeneration, offering a promising therapeutic window to intervene before irreversible neuronal damage occurs.
Building on these advances, Flavii Therapeutics is now preparing regulatory preclinical studies to evaluate the safety, efficacy, and toxicity of its lead compound, with the goal of advancing toward future clinical trials. In parallel, the company is exploring the potential of epigenetic modulation for neurodevelopmental disorders, an area that combines scientific innovation with a strong personal and social commitment.
